676348-45-1

Basic information

• Product Name: (2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE
• Synonyms: (2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE
• CAS NO: 676348-45-1
• Molecular Formula: C8H5Cl2FO
• Molecular Weight: 207.03
• Mol File: 676348-45-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE(676348-45-1)
• EPA Substance Registry System: (2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE(676348-45-1)

Safety Data

• Hazardous Substances Data: 676348-45-1(Hazardous Substances Data)

Usage

General Description

(2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE is a chemical compound with the molecular formula C8H6ClFO and a molar mass of 166.58 g/mol. It is a chlorinated acetyl chloride derivative with a halogenated benzene ring. (2-CHLORO-4-FLUORO-PHENYL)-ACETYL CHLORIDE is commonly used in organic synthesis as a reagent for introducing the (2-chloro-4-fluorophenyl)acetyl group into various organic molecules. It is a versatile building block for the preparation of pharmaceuticals, agrochemicals, and other fine chemicals. Additionally, it is used in the production of dyes, perfumes, and other organic compounds. Due to its acetyl chloride functional group, it is a reactive compound that requires careful handling and storage.

Upstream product

• 177985-32-9 2-(2-chloro-4-fluorophenyl)acetic acid 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Phosphonic acid analogs of fluorophenylalanines as inhibitors of human and porcine aminopeptidases N: Validation of the importance of the substitution of the aromatic ring

A library of phosphonic acid analogs of phenylalanine substituted with fluorine, chlorine and trifluoromethyl moieties on the aromatic ring was synthesized and evaluated for inhibitory activity against human (hAPN) and porcine (pAPN) aminopeptidases. Fluorogenic screening indicated that these analogs are micromolar or submicromolar inhibitors, both enzymes being more active against hAPN. In order to better understand the mode of the action of the most active compounds, molecular modeling was used. It confirmed that aminophosphonic portion of the enzyme is bound nearly identically in the case of all the studied compounds, whereas the difference in activity results from the placement of aromatic side chain of an inhibitor. Interestingly, both enantiomers of the individual compounds are usually bound quite similarly.